EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)

Nicole E Scangarella-Oman iD, Deborah L Butler, John Breton, Derrek Brown, Cara Kasapidis, Helen Millns, Chun Huang, Caroline R Perry, Amanda J Sheets iD, Jeremy Dennison iD, Salim Janmohamed

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01640-24 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Nicole E Scangarella-Oman und 10 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Anti-Bacterial Agents, Piperazines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK - US Office of the Assistant Secretary for Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with ≥1 baseline qualifying (≥10 5 CFU/mL) uropathogen (i.e., pooled microbiological Intent-to-Treat population). Escherichia coli , Klebsiella pneumoniae , and Proteus mirabilis were the most common qualifying uropathogens. Among 1,159 E. coli isolates, 28%, 28%, 15%, and 28% were fluoroquinolone resistant (FQ-R), trimethoprim-sulfamethoxazole resistant (SXT-R), extended-spectrum β-lactamase positive (ESBL+), and multidrug resistant (MDR), respectively. For 114 K . pneumoniae isolates, 25%, 23%, 16%, and 16% were nitrofurantoin resistant, SXT-R, FQ-R, and ESBL+, respectively. Of 67 P . mirabilis isolates, 25%, 21%, and 31% were SXT-R, FQ-R, and MDR, respectively. Gepotidacin MIC 90 values against all qualifying uropathogens and drug-resistant phenotypes ranged from 0.25 to 32 µg/mL, with no isolates of Enterobacterales, Staphylococcus saprophyticus , or Enterococcus faecalis considered resistant to gepotidacin. For all uropathogen drug-resistant phenotypes, gepotidacin MIC 90 values were similar (i.e., lower, equal to, or 1-dilution higher) compared with the MIC 90 of the overall species. Gepotidacin’s efficacy, based on therapeutic, clinical, and microbiological success rates, was generally consistent across phenotypic subgroups of E. coli , K. pneumoniae , and P. mirabilis . This pooled analysis represents a robust, contemporary, clinically relevant, and unbiased (i.e., baseline urine specimens obtained from all enrolled participants regardless of uUTI history) collection of data from community-acquired uUTIs in females. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04020341 and NCT04187144 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsAnti-Bacterial AgentsPiperazinesHumansFemaleMicrobial Sensitivity TestsEscherichia coliProteus mirabilisKlebsiella pneumoniaeDrug Resistance, Multiple, BacterialMiddle AgedNitrofurantoinAdultAgedAcenaphthenesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

acute cystitisantibacterial resistanceextended-spectrum β-lactamasegepotidacinmultidrug resistantnitrofurantoinphenotypeuncomplicated urinary tract infectionuropathogen

Substanzen

Anti-Bacterial AgentsgepotidacinNitrofurantoinPiperazinesAcenaphthenesHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • GSK, Stevenage, Hertfordshire, United Kingdom.
  • GSK, London, United Kingdom.

ORCID-Profile: Nicole E Scangarella-Oman, Amanda J Sheets, Jeremy Dennison

Förderung

  • GSK - US Office of the Assistant Secretary for Preparedness and Response

Zitieren

APA

Scangarella-Oman, N. E., Butler, D. L., Breton, J., Brown, D., Kasapidis, C., Millns, H., Huang, C., Perry, C. R., Sheets, A. J., Dennison, J., & Janmohamed, S. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01640-24

Vancouver

Scangarella-Oman NE, Butler DL, Breton J, Brown D, Kasapidis C, Millns H, et al. Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01640-24

BibTeX
@article{ScangarellaOman2025,
  author = {Scangarella-Oman, Nicole E and Butler, Deborah L and Breton, John and Brown, Derrek and Kasapidis, Cara and Millns, Helen and Huang, Chun and Perry, Caroline R and Sheets, Amanda J and Dennison, Jeremy and Janmohamed, Salim},
  title = {Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01640-24}
}
Kostenlos starten →